The present invention relates to a controlled-release tablet formulation comprising a therapeutically-effective amount of gliclazide or a pharmaceutically-acceptable salt thereof and at least one pharmaceutically-acceptable cellulosic polymer as a release rate-controlling polymer, characterized in that this tablet comprises cellulosic polymer at a proportion of 0.05 to 5% of the total weight of the tablet in its internal phase and at a proportion of 10 to 25% of the total weight of the tablet in its external phase.
